Bayer Bids $2.4 Billion To Acquire Norwegian Biotech Partner Algeta
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer would gain full control of the potential blockbuster prostate cancer therapy, Xofigo, if successful.
You may also be interested in...
Bayer Targets Endometriosis, Fibroids In Oxford University Alliance
Women’s health is the focus of a two- to five-year research alliance between the German conglomerate and one of Europe’s largest biomedical research centers.
Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.
Algeta Recruits Bayer To Deliver Prostate Cancer Drug Alpharadin To Market
Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.